NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects
Press releases
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2 ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 27 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today on 27 April 2017 held its Annual General Meeting (AGM). A summary of the resolutions ...
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelev ...
NeuroVive Pharmaceutical AB Interim Report January – September 2016
New business model generates opportunities
NeuroVive Pharmaceutical publishes English version of annual report for 2014
NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2014 is now available on the company's website www.neurovive.com.The annual report can also be acce ...
NeuroVive Pharmaceutical’s 2013 Annual Report now available
Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...